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Background: Rhabdomyosarcoma (RMS) is the most common type of soft tissue sarcoma in children. The Hedgehog (HH)
pathway is known to develop an oncogenic role in RMS. However, the molecular mechanism that drives activation of the pathway
in RMS is not well understood.
Methods: The expression of HH ligands was studied by qPCR, western blot and immunohistochemistry. Functional and animal
model studies were carried out with cells transduced with shRNAs against HH ligands or treated with HH-specific inhibitors
(Vismodegib and MEDI-5304). Finally, the molecular characterisation of an off-target effect of Vismodegib was also made.
Results: The results showed a prominent expression of HH ligands supporting an autocrine ligand-dependent activation of the
pathway. A comparison of pharmacologic Smoothened inhibition (Vismodegib) and HH ligand blocking (MEDI-5304) is also
provided. Interestingly, a first description of pernicious off-target effect of Vismodegib is also reported.
Conclusions: The clarification of the HH pathway activation mechanism in RMS opens a door for targeted therapies against HH
ligands as a possible alternative in the future development of better treatment protocols. Moreover, the description of a
pernicious off-target effect of Vismodegib, via unfolded protein response activation, may mechanistically explain its previously
reported inefficiency in several ligand-dependent cancers.
Rhabdomyosarcoma (RMS) is the most common type of soft tissue
sarcoma in children. Rhabdomyosarcoma is thought to derive from
embryonic cells committed to developing into skeletal muscle and
is divided into two major subtypes in childhood: embryonal and
alveolar (eRMS and aRMS, respectively). The majority of aRMS
(80–85%) contain one of the reciprocal chromosomal
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translocations: t(2;13)(q35;q14) or t(1;13)(p36;q14) (Barr et al,
1993; Davis et al, 1994). Conversely, no characteristic transloca-
tions have been described in eRMS, which is typically characterised
by loss of heterozygosity on the short arm of chromosome 11
(11p15.5) (Loh et al, 1992) and gains in chromosomes 2, 7, 8, 11,
12, 13 and 17 (Bridge et al, 2000).
Hedgehog (HH) pathway-belonging proteins are considered to
be key regulators of development. Likewise, HH signalling also
plays important roles in adult organisms such as stem cell
maintenance or tissue repair and regeneration. The three HH
proteins present in mammals, Sonic (SHH), Indian (IHH) and
Desert (DHH), are ligands of Patched receptors (PTCH1 and
PTCH2). Ligand-free PTCH inhibits the activation of Smoothened
(SMO) and Gli family zinc finger proteins (GLI1, GLI2 and GLI3)
are proteosomically processed. Upon binding of an HH ligand,
SMO becomes active and prevents GLI proteosomal processing.
GLI is then translocated to the nucleus where regulates GLI-
specific promoters to activate its specific targets (Hahn et al, 1998;
Teglund and Toftgård, 2010).
HH signalling has been shown to be altered (either by mutation
or deregulation) in many cancers including basal cell carcinoma
(BCC), medulloblastoma, small-cell lung cancer and digestive tract
tumours, among many others (Teglund and Toftgård, 2010). The
relationship between HH signalling and RMS was first described in
the Patched knockout mouse by Hahn et al in 1998 who reported
that mice heterozygous for Ptch1 not only develop features
consistent with Gorlin’s syndrome, but also have a high incidence
of eRMS (Hahn et al, 1998). Consistent activation of the pathway is
well established and generally accepted in RMS (Zibat et al, 2010;
Pressey et al, 2011; Satheesha et al, 2015). However, controversy
exists regarding the importance of mutation-driven constitutive
activation of the pathway in RMS patients. Some works reported
that neither PTCH mutations nor activating SMO mutations
appear to be implicated in activation of the pathway (Calzada-
Wack et al, 2002; Pressey et al, 2011); however, other authors
reported losses in the PTCH region 9q22 in one third of eRMS and
loss of SUFU has also been reported in 18% of eRMS (Bridge et al,
2000; 2002; Tostar et al, 2006). Additionally, genomic amplification
of chromosomal region 12q13-15 containing GLI1 gene has been
identified only in a subset of aRMS tumours (Bridge et al, 2002;
Pressey et al, 2011). Consequently, the activator mutations
reported to date can only account – in the best scenario – for
the activation of the pathway in small subsets of patients.
Moreover, a possible role of methylation of the PTCH1 promoter
has been described and seems to be able to reduce WT allele
expression in the Patched knockout mouse. However, this
effect is only significant if concomitant with an oncogenic
mutation of the first allele of this gene (Uhmann et al, 2005),
thereby reducing its potential in tumours with no PTCH1
mutation; therefore, the mechanism of activation remains elusive
for the majority of patients.
On the other hand, several publications with xenografted RMS
have raised the possibility of effectively reducing tumour growth
(Eichenmu¨ller et al, 2010; Tostar et al, 2010; Yamanaka et al, 2011)
or even an impaired tumour initiation (Zibat et al, 2010) after
pharmacologic inhibition of the pathway. In fact, small molecular
antagonists of SMO entered clinical phase I and II trials for HH-
driven neoplasias (Von Hoff et al, 2009; Lin and Matsui, 2012).
Recently, in 2012, the SMO inhibitor Vismodegib was the first HH
signalling pathway-targeting agent approved by the U.S Food and
Drug Administration for the treatment of metastatic or locally
advanced BCC (Abidi, 2014).
Despite the knowledge gathered to date, the mechanism that
drives activation of the pathway in RMS is not well understood and
the possible role of DHH or IHH in the pathogenesis of RMS has
not been studied. Although activation of the pathway is well known
in RMS, herein we report for the first time a preponderant
expression of DHH and IHH ligands in RMS, which supports the
existence of an autocrine ligand-dependent activation of the HH
pathway in this neoplasia. The possible benefits of pharmacologic
SMO inhibition (Vismodegib) and HH ligand blocking (MEDI-
5304) are also studied. Furthermore, the genetic silencing of the
ligands led to a clear impairment of tumour growth of xenografted
tumours. Finally, given that we observed a possible adverse effect of
Vismodegib which promotes cell invasion in an HH-independent
manner, the molecular characterisation of this putative undesired
off-target effect is also provided.
MATERIALS AND METHODS
Human samples. Thirty-three frozen RMS tumours were
obtained from our private collection (ISCIII C.0002311) and 20
from the CWS (‘Cooperative Weichteilsarkom Studiengruppe’)
tissue bank (Stuttgart, Germany). Paraffin-embedded RMS tumour
samples were obtained from our Pathology Department. Written
informed consent according to the Declaration of Helsinki was
obtained from all patients or their legal guardians and the study
approved by the Vall d’Hebron Research Ethics Committee.
Cell culture and drug treatment. Cell lines RH30 and RH4
correspond to aRMS with PAX3/FOXO1 translocation, RH18 to a
translocation-negative aRMS and RD and HTB82 to eRMS
subtype. Some authors have attributed the HTB82 cell line to a
rhabdoid tumour since it bears a mutation in the SMARCB1 gene
(Khan et al, 2001; Hinson et al, 2013). All RMS cell lines were
previously authenticated by STR-based DNA profiling, grown in
MEM media (Biowest, Barcelona, Spain), supplemented with 10%
foetal bovine serum (Sigma-Aldrich, Madrid, Spain), 2mM L-
glutamine, 1mM sodium pyruvate and 1 non-essential amino
acids (all reagents from Biowest). All cell lines were obtained from
American Type Culture Collection, except RH18 and RD cell lines
which were a kind gift from Dr Beat Scha¨fer. The SMO inhibitor
Vismodegib (GDC-0449) was purchased from Selleckchem
(Madrid, Spain). The antibody MEDI-5304 was kindly provided
by MedImmune (Cambridge, UK).
RNA extraction, reverse transcription and real-time PCR. Total
RNA was extracted using the RNeasy Mini Kit (Qiagen, Hilden,
Germany). Two micrograms of total RNA were reverse-transcribed
using 200U of MMLV (Promega, Madrid, Spain) and random
primers (Invitrogen, Thermo Fisher Scientific, Madrid, Spain). PCRs
based on the TaqMan assay (Applied Biosystems, Thermo Fisher
Scientific, Madrid, Spain) was performed to detect SHH, IHH, DHH
and GLI1 (Hs00179843_m1, Hs00745531_s1, Hs00368306_m1 and
Hs00171790_m1). The housekeeping gene TBP (TATA-binding
protein, Hs00172424_m1) was used as internal control. Relative
levels of each mRNA were tested in triplicate and quantified by the
method of Livak and Schmittgen (2001).
Western blot. Tumour samples were disrupted with a Pellet Pestle
Motor (Sigma-Aldrich) in RIPA lysis buffer (Thermo Fisher
Scientific, Madrid, Spain). Twenty micrograms of protein were
separated on 8–15% SDS–PAGE gels and transferred to PVDF
membranes (Life Sciences, Sigma-Aldrich, Madrid, Spain), blocked
in 5% BSA and incubated with the appropriate antibodies: anti-
SHH 06-1106 (1 : 2000, Millipore, Madrid, Spain), anti-IHH
MABF23 (1 : 1000, Millipore), anti-DHH H00050846-B01P
(1 : 500, Novus Biologicals, Abingdon, UK), anti-GLI1 clone
EPR4523 (1 : 1000, Millipore), anti-GLI2 R770 (1 : 1000, Cell
Signaling, Barcelona, Spain), anti-PTCH1 06-1102 (1 : 1000,
Millipore), anti-Cyclin D2 sc-593 (1 : 200, Santa Cruz Biotechnol-
ogy, Heildelberg, Germany), anti-TRIB3 antibody 07-2160
(1 : 1000, Millipore), anti-CHOP sc-7351 (1 : 200, Santa Cruz
Biotechnology), anti-FAK #3285S (1 : 1000, Cell Signaling),
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anti-p-FAK #3283 (1 : 500, Cell Signaling), anti-ATF4 #11815
(1 : 1000, Cell Signaling) and anti-PARP1 #9542 (1 : 1000, Cell
Signaling). Anti-aTubulin ab7291 (1 : 5000, Abcam, Cambridge,
UK) or anti-Actin sc-1616 (1 : 10000, Santa Cruz Biotechnology)
antibodies were used as loading control. After incubation with
appropriate HRP-conjugated secondary antibodies, ECL Prime
reagent (GE Healthcare, Barcelona, Spain) was used for chemilu-
minescence detection.
Immunohistochemistry. Paraffin-embedded tissues were sec-
tioned, deparaffinised and rehydrated, followed by antigen retrieval
in 10mM citrate buffer (DAKO, Agilent Technologies, Barcelona,
Spain). Samples were blocked and incubated with antibodies
against SHH (06-1106, Millipore), IHH (MABF23, Millipore) or
DHH (H00050846-B01P, Novus Biologicals), all diluted 1 : 200.
The three HH antibodies yielded mainly membrane labelling, as
expected. Samples were evaluated using a semiquantitative method
(Rhodes et al, 2000) regarding the percentage of cells with
membrane labelling, excluding blood vessels (0%,p25%, 26–50%,
51–75% and X75% corresponding to a score of 0, 1, 2, 3 and 4,
respectively) plus intensity (from 0 to 3) of the labelling (total score
range: 0 to 7).
Plasmids and lentiviral transduction. Genetic inhibition of the
HH ligands, GLI1 and TRIB3 was performed by shRNAs cloned
into the lentiviral vector pGIPZ (GE Dharmacon, Lafayette, CO,
USA). Positively transduced cells were selected with puromycin
(1 mgml 1, Sigma-Aldrich). Knockdown efficiency of each shRNA
was analysed by western blot. Six different shRNAs were tested by
western blot with the aim of selecting the best option for each
target. The GE Dharmacon IDs of selected clones were:
V3LHS_82400 (shSHH), V3LHS_336297 (shIHH), V3LHS_401021
(shDHH), V2LHS_262249 (shGLI1). For TRIB3, four different
shRNAs were tested and the selected option was V3LHS_644655
(shTRIB3). Functional assays were performed 7 days after
infection.
WST-1 assay. Cell proliferation was measured by WST-1 colori-
metric assay (Sigma-Aldrich), following the manufacturer’s
instructions. Cells seeded at low density were allowed to proliferate
for 4 days. WST-1 reagent was then added and, after 3 h,
absorbance was measured at 440 nm. All conditions were assayed
per triplicate in three independent experiments.
Transwell assay. Cell invasiveness was assessed by Transwell assay
(Corning, Barcelona, Spain ). Briefly, 105 cells were resuspended in
serum-free MEM media supplemented with the appropriate drug
and plated in the upper chamber previously coated with BD
MatrigelTM (Corning) in an 8 mm pore size transwell (Corning).
After 24 h, cells migrated to the lower surface of the membrane
were stained in 5 ngml 1 of Hoechst33342. Cells were counted
under a light microscope in three independent wells for each
experiment and three independent experiments were performed.
Animal models. Five-week-old female SCID and SCID-Beige mice
were purchased from Charles River Laboratories (Barcelona,
Spain). Animals were housed in specific-pathogen-free conditions
with food and water available ad libitum. For the primary tumour
model, 106 RD cells stably transduced with shRNA expressing
lentiviral vectors were injected orthotopically in the right
gastrocnemius muscle of SCID mice whereas the left muscle was
injected with control cells (n¼ 5 per condition). Limb volume and
body weight were measured every 2 days. For the metastasis model,
106 RH30 cells (suspended by pipetting in PBS) were intravenously
injected into tail veins of SCID-Beige mice. Animals were treated
every other day with either DMSO (Control) or 40mg kg 1
Vismodegib, as previously described (Chan et al, 2012; Moshai
et al, 2014) and killed following three main criteria: (1) tumour size
(when measurable, 42 cm), (2) weight loss (410% of total body
weight) or (3) poor general status of the animal. All animals were
killed following these guidelines and none were ever allowed to
suffer or reach a moribund state. Post-mortem analysis revealed
that all animals killed during the study presented macroscopic
metastasis. Conversely, all the animals that reached the end of the
study as healthy were free of macroscopic metastasis. All
procedures were previously approved by the Ethics Committee of
Animal Experimentation of the Vall d’Hebron Research Institute
(CEEA 30/14).
Microarray expression analysis. Microarray hybridisation was
carried out with 200 ng of total mRNA in an Affymetrix (Thermo
Fisher Scientific, Madrid, Spain) microarray 7000G platform and
the Genechip Human Gene Array 2.0. Quality of isolated RNA was
first assessed by Bioanalyzer Assay (Agilent, Barcelona, Spain).
Briefly, sense ssDNA was generated from total RNA with the
GeneChip WT Plus Reagent Kit from Affymetrix according to the
manufacturer’s instructions. Results were submitted to the GEO
microarray database (GSE77996).
RESULTS
SHH is expressed in a small subset of RMS cell lines and
tumours, whereas IHH and DHH are the predominant HH
ligands in RMS
RMS cell lines. SHH mRNA levels were studied in five cell lines
representing the main RMS subtypes. While the two eRMS cell
lines expressed SHH, levels in the three aRMS cell lines were
extremely low (Figure 1A). Conversely, IHH and DHH expression
levels were noteworthy in all cell lines analysed without exception
(Figure 1A). Additionally, the results shown by western blot
(Figure 1B) concurred with the qPCR results. Thus, the SHH
protein level was extremely low in all alveolar cell lines, and
moderate in the embryonal cells. By contrast, IHH showed high
levels in all cell lines. DHH showed high expression levels in the
embryonal cell lines analysed and a moderate level of expression
was shown for the alveolar cells (with the exception of RH30, with
very low expression level).
RMS tumours. Concordantly with results in cell lines, SHH
expression was negligible in the majority of RMS samples.
However, approximately 30% of patients in a well-separated
positive subpopulation showed remarkable mRNA SHH expression
by real-time PCR (Figure 1C) and western blot (Figure 1D). In
contrast, IHH and DHH levels were moderate, high or very high in
all patients analysed by both qPCR (Figure 1C) and western blot
(Figure 1D). No significant differences were observed between
aRMS and eRMS (Supplementary Figure S1).
IHC in archival paraffin-embedded human RMS tumour sections
also revealed predominant expression of DHH and IHH ligands
in tumour cells. The majority of the tumours analysed showed
very low or negligible SHH expression (15 out of 23, 65%), whereas
the remaining 35% of samples showed low or moderate SHH levels
(Figure 1H). Conversely, IHH and DHH were very highly
expressed in the majority of samples, with a maximum expression
of both proteins (semi-quantitative score 7) in 14 of 23 samples
(61%), and semi-quantitative score values X4 for IHH in 18 of 23
samples (78%) and 20 of 23 samples for DHH (87%).
Representative photographs of SHH, IHH and DHH immunohis-
tochemistries (E, F and G, respectively) are shown in Figure 1 with
two magnifications.
The presence of HH ligands correlates with activation of the
pathway, thereby suggesting an autocrine mechanism. The
presence of HH ligands in human RMS tumours was correlated
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Figure 1. IHH and DHH are widely distributed in RMS whereas SHH is only expressed in a small subset of patients. (A) mRNA levels
of SHH, IHH and DHH in five cell lines (RH30, RH4, HTB82, RD and RH18). Values are expressed as DCT value and the horizontal line depicts the
mean of the values for the cell lines analysed. (B) Western blot showing the levels of the HH ligands in the same cell lines. The HEK cell line was
used as a positive control. (C) Quantitative real-time PCR analysis of HH ligand expression in patients. Values are expressed as DCT value and
the horizontal line depicts the mean values (n¼ 53). (D) Western blot showing HH ligand levels in eight RMS patients (aRMS, alveolar RMS; eRMS,
embryonal RMS). Tubulin was used as loading control (TUB). The presence of SHH (E), IHH (F) and DHH (G) in archival human samples was
examined by immunohistochemistry at low magnification for a general view of the section (left), and the area indicated by a square is shown
magnified on the right for a more detailed view. Bars: 100 mm. (H) Semi-quantitative evaluation of the expression of the three ligands in patient
samples (n¼27). Horizontal lines depict the mean score for each marker.
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with the expression of one of the main downstream targets of the
pathway, GLI1 (Figure 2A–D). The results showed significant
correlation for SHH (P¼ 0.0197), DHH (P¼ 0.0268) and the sum
of the three HH ligands (P¼ 0.0189). No significant correlation
was obtained for IHH, although a trend was also observed.
Furthermore, the genetic downregulation by shRNAs of the HH
ligands and GLI1 (decrease of ligands and GLI1 is shown in
Supplementary Figure S2) revealed a significant downregulation of
some components and downstream targets of the pathway in the
cell lines RD and RH4. Thus, IHH, DHH and GLI1 down-
regulation resulted in a marked decrease in GLI1, GLI2 and
PTCH1, whereas SHH downregulation did not affect GLI1
expression but clearly decreased GLI2 and PTCH1 (Figure 2E
and F). Conversely, in RH30 cell line that bears a GLI1-
amplification none of the ligands significantly changed GLI1
expression. However, despite GLI1 amplification, the deprivation
of SHH, IHH and DHH produced a significant reduction in GLI2
and PTCH1 expression (Figure 2G).
Deprivation of IHH and DHH rendered a reduction in cell
proliferation. The effects of the shRNA-mediated IHH and DHH
deprivation significantly reduced cellular proliferation of the cell
lines RD and RH4 (Figure 3A and C). Unsurprisingly, no effects
were observed for RH30 cells (Figure 3E). Interestingly, the
pharmacologic effect of the HH ligand-blocking antibody MEDI-
5304 produced comparable lessening in proliferation for RD and
RH4. These cell lines were also sensitive to the SMO inhibitor
Vismodegib and to the GLI1 shRNA. Once again, the RH30 cell
line was completely insensitive to both ligand deprivation and
MEDI-5304 antibody treatment, probably due to its GLI1-
amplification. Only shRNA of GLI1 and Vismodegib treatment
produced an antiproliferative effect on this cell line. Concordantly,
Cyclin D2 levels were increased in cell lines RD and RH4 upon
IHH, DHH and GLI1 deprivation (Figure 3B and D), thereby
suggesting a cell cycle arrest at G1. No effects on this cell cycle
effector were observed in the RH30 cell line (Figure 3F). Moreover,
RD and RH4 RMS cells with downregulation of IHH and DHH
showed a reduction in the percentage of cells in G2, thereby
suggesting a cell cycle impairment (Figure 3G). Once again, the
RH30 cell line showed no changes (not shown). Although a slight
increase in early apoptotic cells and concordant PARP-1 cleavage
was detected in the RD cell line, the results in the other two cell
lines ruled out apoptosis as a general mechanism able to account
for the decrease in the number of cells observed (Supplementary
Figure S3). Moreover, no significant changes in total dead cells
were observed for any of the cell line (not shown). The
pharmacologic downregulation of the pathway was assessed by
measuring Gli1 mRNA levels (Figure 3H–J).
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Figure 3. Effects of the depletion of HH ligands on cell proliferation. (A, C and E) Relative proliferation, expressed as a reduction in WST
uptake, compared to control cells (100%). The experiments were performed in the following samples: control (empty vector or vehicle) cells, cells
transduced with shRNAs for SHH, IHH, DHH and GLI1 and, finally, cells treated with Vismodegib (50mM) or the HH blocking antibody MEDI-5304
(30mg/ml) after 4 days. The RMS cell lines analysed were RD, RH4 and RH30. (B, D and F) Western blots showing the accumulation of Cyclin D2
(CYC D2) in RD and RH4 cells. No changes were detected in RH30. (G) Cells transduced with shRNAs for IHH and DHH showed a slight reduction
in the percentage of cells in G2, which indicates an impairment in the cell cycle. Percentages of cells in G1 and G2þ S are indicated in the plots.
Significance: *Po0.05, **Po0.01, ***Po0.001. (H–J) Relative GLI1 mRNA expression after Vismodegib or MEDI-5304 treatment.
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Genetic impairment of HH ligand expression produced a severe
tumour growth reduction in SCID mice. Six and a half weeks after
intramuscular RD cell injection, excised tumours stably expressing
shRNAs against SHH, IHH, DHH and GLI1 were clearly smaller –
or even in some cases were unable to grow – compared to the
control tumours (empty vector) (Figure 4A). The average weight of
the tumours was also clearly lower (Figure 4B). The difference was
particularly dramatic after SHH and GLI1 downregulation
(o25%) but also noteworthy for IHH and DHH downregulation
(o40%). The kinetics of growth were clearly reduced in all cases
(Figure 4C–F), with statistically significant differences from 5 to 6
weeks onwards. All shRNA targets were found to be downregulated
as expected in tumours at the end point (Figure 4G).
SHH played a crucial role for the invasive phenotype in ligand-
dependent RMS cells and paradoxical enhancement of invasive-
ness by Vismodegib. In contrast to the effects seen on cell
proliferation, the genetic inhibition of IHH and DHH produced no
effects on cell invasiveness. Surprisingly, the effect of the down-
regulation of SHH in terms of invasiveness was noteworthy in RD
and RH4 cell lines (Figure 5A and B). Once again the cell line
RH30 was refractory to ligand deprivation (Figure 5C). The effects
of MEDI-5304 antibody on invasiveness were statistically not
significant. Unexpectedly, Vismodegib enhanced the invasive
properties of all three cell lines by two-fold. These surprising
results, together with the fact that the invasiveness of the RH30 cell
line was likewise increased despite its GLI1-amplification (down-
stream of SMO), suggested an off-target effect of Vismodegib on
cell invasiveness. Similar results were seen in mice treated with
Vismodegib that were more prone to developing metastasis after a
tail vein injection of RH30 cells (Figure 5D). Thus, in the control
group (vehicle), only 55% of mice developed metastasis, whereas in
the group treated with Vismodegib, all mice metastasised.
The paradox effect of Vismodegib on the invasiveness of RMS
cells is mediated by off-target activation of the unfolded protein
response pathway and concomitant phosphorylation of FAK.
A cDNA microarray was performed to identify pathways
differentially regulated between untreated and Vismodegib-treated
cells. The expression profile analysis was made in three cell lines
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(RD, RH4 and RH30). Results revealed an overexpression of
several stem components of the unfolded protein response (UPR)
pathway (PERK, CHOP, TRIB3) and some downstream compo-
nents, particularly those involved in cell invasion such as ATG16/1,
HMOX, STAT3, STAT5 or cell proliferation such as ASNS, FGFR2
and IL8 (Figure 6A–D). Western blots showed a very consistent
increase in the expression of CHOP and TRIB3 in the three RMS
cell lines analysed. Additionally, the stem component of the UPR
pathway ATF4, which was not detected as overexpressed in the
array, also showed an increase in both protein amount and
phosphorylation (Figure 6D). Interestingly, the treatment with
Vismodegib also produced a concomitant increase in phosphor-
ylation of FAK (P-FAK), a protein often involved in invasion and
metastasis. All cell lines analysed showed a very consistent increase
in P-FAK, whereas total FAK levels remained stable in all cases
(Figure 6E). Given that the cell lines studied covered all the main
subtypes of RMS, the results strongly suggest that UPR activation
may be a general mechanism of cell invasiveness in RMS under
Vismodegib treatment and not a mere peculiarity of a single cell
line. Furthermore, analysis of the Davicioni data set revealed the
existence of interesting correlations between TRIB3 expression and
RMS progression (Supplementary Figure S4). Moreover, the
shRNA-mediated genetic inhibition of TRIB3 (shown in
Figure 6F) together with Vismodegib treatment not only hindered
the expected increase in invasion of cells treated with Vismodegib,
but also produced a plunge in this cell invasion. TRIB3 genetic
downregulation alone produced a moderate reduction in cell
invasion (Figure 6G).
DISCUSSION
Mutation-driven cancers such as those associated with Gorlin’s
syndrome were the first in which an oncogenic role of the HH
pathway was described (Hahn et al, 1996; Johnson et al, 1996). The
archetypical molecular basis for the development of the malig-
nancies associated with Gorlin’s syndrome is the PTCH1 loss of
function which leads to constitutively activated HH signalling even
in the absence of a ligand. Given that the mutation of components
of the HH pathway in RMS appears to be rare (Calzada-Wack et al,
2002) – except in Gorlin’s syndrome that accounts for a very low
percentage of RMS patients – a plausible hypothesis is that,
regarding HH pathway activation, the majority of RMS are ligand-
dependent tumours. To prove this hypothesis, it is crucial to
demonstrate the presence of functional HH ligands in the tumours.
However, an earlier report on HH ligand expression showed very
low or undetectable SHH levels in RMS tumours and cell lines
(Calzada-Wack et al, 2002), thereby pointing to a ligand-
independent activation of HH signalling in RMS. We here show
for the first time that IHH and DHH – and, in a subset of cases,
also SHH – are present in RMS tumour cells with concomitant
variations in the expression of HH downstream targets, thus
pointing to an autocrine mechanism of HH activation in which
ligands may be both produced and responded to by the same
tumour cells. Concordantly, the work of Satheesha et al (2015)
ruled out paracrine activation of the pathway in RMS cells in
in vivo mouse models. The reduction in proliferation upon IHH
and DHH genetic deprivation in the cell lines RD and RH4 clearly
indicates a crucial role of these ligands in the activation of the
pathway and, therefore, is a further indication of ligand-dependent
activation in these cell lines. The refractoriness of the cell line
RH30, which bears a 10-fold GLI1 amplification (Calzada-Wack
et al, 2002) is especially noteworthy. Presumably, GLI1 amplifica-
tion makes the cell behave as ligand-independent, since the
amplification bypasses the canonical ligand-dependent activation
of the pathway. This cell line may be a paradigmatic example to
illustrate the probable existence of a subset of patients with GLI1
amplification, as previously suggested (Calzada-Wack et al, 2002),
which may be refractory to possible therapies based on ligand
inhibition. According to that interesting previous work, GLI1
amplification seems to be alveolar-subtype specific (or at least is
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more frequently described in this subtype). However, the activation
of the pathway in the majority of RMS tumours (including all
eRMS and an undetermined proportion of aRMS) cannot be
explained by this mechanism. On the other hand, cell lines RH4
and RD would represent tumours without mutations in HH
pathway components, the oncogenicity of which strongly depends
on ligand presence. The strong dependency on ligands, together
with the fact that this phenotype presumably represents the
majority of RMS patients, enables alternative therapeutic
approaches based on ligand blocking in this neoplasia which
may have wide translational potential.
The cell proliferation reduction drop observed in ligand-
dependent cell lines after depletion of HH ligands strongly suggests
that this is associated with a cell cycle alteration and the observed
Cyclin D2 accumulation points to a G1-phase cell cycle arrest.
Indeed, several of the genes activated by GLI proteins (i.e., Cyclin
D) are key regulators of G1/S transition (Kasper et al, 2006).
Interestingly, in the cell lines RD and RH4, the reduction in cell
proliferation induced by pharmacologic inhibition is significant
and comparable for both the ligand-blocking antibody MEDI-5304
and the SMO inhibitor Vismodegib. However, in RH30 cell line the
inhibitory effect of Vismodegib on proliferation was probably an
off-target effect, since GLI1 amplification is expected to result in
insensitivity to SMO inhibitors. Conversely, the effect of MEDI-
5304 appears to be pathway-specific since it did not impact on the
RH30 cell line. Consequently, MEDI-5304 showed higher speci-
ficity and similar potency in the blocking of the HH pathway-
induced proliferation. It is important to emphasise that the therapy
of mutation-driven cancers by inhibition of the HH pathway
constituents can only be successful if these are situated down-
stream of the acquired mutation or amplification (Heretsch et al,
2010). Conversely, ligand-dependent cancers are expected to be
sensitive to therapeutic strategies based on ligand targeting. The
results herein presented, as commented above, point to a reduction
of RMS cell proliferation when treated with the antibody MEDI-
5304. Interestingly, this antibody blocks SHH and IHH but fails to
recognise DHH (Michaud et al, 2014). It is conceivable that the
high level of expression of DHH in RMS may partially account for
the moderate anti-proliferative effect of MEDI-5304. Thus, despite
being the least active of the three HH ligands, DHH can
significantly activate GLI1 expression (Pathi et al, 2001). Therefore,
we cannot rule out that DHH in RMS plays a more important role
than hitherto expected.
Although the shRNA-mediated downregulation of the ligands
was not complete and performed separately for each ligand, the
effects observed on tumour growth were remarkable. Thus, the
downregulation of each single HH ligand clearly impaired tumour
growth, suggesting that the participation of all ligands is crucial for
RMS pathogenesis. The strong effect on tumour growth of SHH
deprivation is particularly noteworthy. Because downregulation of
SHH had no effect on cell proliferation in vitro, this ligand
probably has to interact with the tumour microenvironment to
execute its RMS-promoting functions. In this regard, the connec-
tion between an aberrant HH ligand secretion and the paracrine
stimulation of stromal cells it is particularly interesting (Curran
and Ng, 2008; Yauch et al, 2008). Indeed, also in RMS, SHH
secretion may lead to a production of VEGF and IGF by the HH-
stimulated stromal cells which, in turn, may affect angiogenesis of
the growing tumour. Both factors, VEGF and IGF are clues to
angiogenesis (Shigematsu et al, 1999; Bach, 2015).
The anti-oncogenic effect of the HH ligand deprivation is
not restricted to cell proliferation. An essential role of HH
pathway on epithelial to mesenchymal transition and/or invasive-
ness in a broad spectra of cancers (Lee et al, 2015; Lei et al, 2015;
Liu et al, 2015) including RMS (Oue et al, 2013) has previously
been well established. However, the possible influence of HH
ligands on RMS cell invasion has not been elucidated to date. This
work provides data to demonstrate for the first time a crucial role
of SHH in the promotion of an invasive phenotype in RMS cells.
Conversely, IHH and DHH appear not to influence invasion,
pointing to a specific role of SHH in this aspect of tumour
progression.
While SMO antagonists are active in BCC and in medullo-
blastoma, clinical results in other solid tumours, whereby
mutational activation of the pathway is absent, have been less
encouraging (McMillan and Matsui, 2012). For instance, in
metastatic pancreatic cancer, a trial was prematurely halted after
patients in the Saridegib plus Gemcitabine arm were found to
have a higher rate of disease progression and lower median survival
than those receiving Gemcitabine alone (McMillan and Matsui,
2012). Other attempts in advanced colorectal, ovarian and
pancreatic cancers did not render significant positive results
either (McMillan and Matsui, 2012; Catenacci et al, 2015). Indeed,
in the study of Catenacci et al (2015), experiments in mice
treated with Vismodegib revealed a worrying reduction in the
survival median – albeit not statistically significant – compared to
the control group. A plausible reason for these failures
was that these cancers were ligand-dependent and not driven
by mutations in specific components of the pathway. This
raises the possibility of pharmacologic ligand inhibition, which
may be considered an appealing therapeutic alternative in
ligand-dependent cancers. Our findings in RMS show for the first
time a relationship between an SMO inhibitor treatment
and triggering of the intricate process of cell invasion via UPR
pathway activation.
Activation of the UPR pathway has been suggested to play a role
in cancer (Ma and Hendershot, 2004). UPR is thought to be
initiated by three endoplasmic reticulum (ER) stress sensors:
protein kinase RNA-like ER kinase (PERK), activating transcrip-
tion factor 6 (ATF6) and inositol-requiring enzyme 1a (IRE1a)
(Hetz et al, 2013). The fact that TRIB3, CHOP and ATF4 are
essential downstream effectors of the pathway triggered by PERK
and that they are activated (Figure 6) suggests that the activation of
this response – after Vismodegib treatment – would be dependent
on this UPR sensor, at least in RMS. To date, the potential UPR
role in cancer is not completely understood and no relevant
previous information on the implication of UPR in RMS
progression was found; however, one of the most remarkable
UPR functions in cancer progression is the promotion of
invasiveness, including the promotion of some matrix metallopro-
teinases, extracellular matrix remodelling and angiogenesis
(Dejeans et al, 2015). Interestingly, the concomitant increase in
FAK phosphorylation (P-FAK) has been previously related to UPR
activation as a mechanism able to induce cell survival, inhibit
apoptosis and reduce chemosensitivity in cancer (Tang et al, 2012),
thereby suggesting a pro-oncogenic potential associated with this
mechanism. Moreover, the genetic inhibition of TRIB3 not only
blocked the cell invasion increase but also promoted a clear
sensitisation of cells to Vismodegib treatment, thereby pointing to
a role for this protein in RMS chemoresistance. Taken together, the
data reported and the discovery of this mechanism may help
researchers and companies interested in the development and
application of SMO inhibitors in cancer.
The clarification of the HH pathway activation mechanism in
RMS, which has remained elusive to date, opens a door for targeted
therapies against HH ligands as a possible alternative in the future
development of better treatment protocols for RMS. Moreover, as a
secondary point albeit not less important, the description of a
pernicious off-target effect of Vismodegib may explain its
previously reported inefficiency in several ligand-dependent
cancers or even the premature halting of some of them owing to
survival worsening. Therefore, the findings herein described may
have significant translational implication not only for RMS but also
for other HH ligand-dependent cancers.
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